- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02491177
Mother and Infant Visit Adherence and Treatment Engagement Study (MOTIVATE!)
22 april 2021 uppdaterad av: University of Colorado, Denver
Maximizing Adherence and Retention for Women and Infants in the Context of Option B+
This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+.
The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) .
The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care.
The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
In order to eliminate new pediatric HIV infections, save maternal lives, and simplify antiretroviral therapy (ART) implementation in settings with generalized HIV epidemics, current World Health Organization (WHO) guidance recommends lifelong triple ART for all pregnant and breastfeeding women (Option B+).
However, despite the promise of Option B+ to remove logistical barriers and to promote maternal health through life-long ART, this strategy brings challenges.
Key amongst these challenges are adherence to ART and continuous retention in HIV care, especially for women who do not require ART for their own health.
Barriers to adherence and retention in care for prevention of mother-to-child transmission (PMTCT) have been identified at the individual, interpersonal, community, and health facility levels; yet specific barriers in the context of Option B+ are not well understood.
The investigators' study will be conducted at 20 health facilities and associated communities in Nyanza Province, Kenya where Mother to Child Transmission (MTCT) rates prior to Option B+ roll-out remained near 10%, despite the wide availability of PMTCT services.
As Option B+ is scaled up in Kenya, it is essential to identify effective methods to ensure long-term adherence and retention in care for mother-baby pairs, throughout pregnancy, breastfeeding, and beyond.
Building on the investigating team's prior research experience in this setting, the investigators propose to gain understanding of and address potential barriers at the individual, community, and health facility levels through formative research with HIV-positive pregnant and postpartum women, their male partners, and health care providers.
This information will be used to refine two proposed interventions that are highly likely to maximize ART adherence and retention in care among HIV-infected pregnant women and HIV-exposed infants.
These interventions will be rigorously tested in rural Kenya, using a cluster randomized 2x2 factorial design.
The evidence-based interventions to be tested will include 1) community Mentor Mothers (cMM) who will provide support for ART adherence and retention in care for HIV-positive women in the community and 2) individually tailored, theory based mobile phone text messages to help retain women and infants in HIV care.
The investigators' overall goal is to determine which intervention (or combination of interventions) maximizes ART adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.
The investigators' primary outcomes will include ART adherence at 12 months postpartum and retention in care, measured by a documented HIV care visit within 90 days prior to 12 months postpartum.
Secondary outcomes will include MTCT at 6 weeks, 12 months and 18 months; as well as maternal viral loads and CD4 counts.
Results from this study will inform the scale-up of Option B+ in Kenya by identifying effective interventions and combinations of interventions that can reduce barriers and increase facilitators of optimal ART adherence and retention in care with the aims of reaching the elimination of mother to child transmission of HIV and significantly improving maternal health.
Studietyp
Interventionell
Inskrivning (Faktisk)
1338
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Nairobi, Kenya
- Kenya Medical Research Institute
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Kvinna
Beskrivning
Inclusion Criteria:
- Age 18 years or older,
- HIV-infected pregnant women and their HIV-exposed infants pairs,
- attends the antenatal care (ANC) clinic at one of the study sites.
Exclusion Criteria:
- Less than 18 years of age,
- HIV-infected women not currently pregnant,
- not HIV-infected at the time of the first ANC visit.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: cMM and Text Messaging
Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention.
The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
|
Home visits from community mentor mothers
Text messages received on mobile phone
|
|
Övrig: cMM Only
Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
|
Home visits from community mentor mothers
|
|
Övrig: Text Messaging Only
Participants randomized to this arm will receive the mobile phone text messaging intervention only.
The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
|
Text messages received on mobile phone
|
|
Inget ingripande: Neither cMM nor Text Messaging
Participants randomized to this arm will receive standard of care with no interventions.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Self-reported adherence on antiretroviral therapy
Tidsram: 12 months post-partum
|
Self-report
|
12 months post-partum
|
|
Adherence on antiretroviral therapy
Tidsram: 12 months post-partum
|
Viral load<100 copies/ml based on medical records
|
12 months post-partum
|
|
Adherence on antiretroviral therapy (infant)
Tidsram: 12 months post-partum
|
Use of ARVs for the infant
|
12 months post-partum
|
|
Retention in care
Tidsram: 12 months post-partum
|
Proportion of women who have an HIV care visit within 90 days at 12 months after the birth
|
12 months post-partum
|
|
Adherence on antiretroviral therapy (dried blood spots)
Tidsram: 12 months post-partum
|
Viral load<100 copies/ml based on dried blood spots
|
12 months post-partum
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maternal CD4 count change
Tidsram: 6 months after baseline
|
Change in CD4 count baseline to 6 months after baseline
|
6 months after baseline
|
|
Maternal viral load count change
Tidsram: 6 months after baseline
|
Change in viral load from baseline to 6 months after baseline
|
6 months after baseline
|
|
Infant retention in care (feeding method)
Tidsram: 12 and 18 months
|
Infant feeding method
|
12 and 18 months
|
|
Infant retention in care
Tidsram: 12 and 18 months
|
Retention in care through 12 and 18 months
|
12 and 18 months
|
|
Infant retention in care (survival status)
Tidsram: 12 and 18 months
|
Survival status of infant
|
12 and 18 months
|
|
Uptake of intervention services (Number/types of text messages sent)
Tidsram: 3 years
|
Number/types of text messages sent
|
3 years
|
|
Uptake of intervention services (receipt of text messages)
Tidsram: 3 years
|
Receipt of text messages
|
3 years
|
|
Uptake of intervention services (home visits)
Tidsram: 3 years
|
Number of home visits received
|
3 years
|
|
Uptake of intervention services (support groups attended)
Tidsram: 3 years
|
Number of support groups attended.
|
3 years
|
|
Mother-to-Child-Transmission
Tidsram: 6 weeks, 9 months and 18 months
|
Result of infant HIV test at 6 wks, 9,18 months
|
6 weeks, 9 months and 18 months
|
|
Infant testing
Tidsram: 6 weeks, 9 months and 18 months
|
Uptake and date of infant testing
|
6 weeks, 9 months and 18 months
|
|
Infant enrollment in care
Tidsram: 6 weeks
|
Infant enrollment in HIV care
|
6 weeks
|
|
Male partner involvement
Tidsram: 12 months post-partum
|
Composite variable including Y/N response to indicate if male partner attended a health visit with his female partner, encouraged facility delivery, reminded to take HIV medication, reminded to go for HIV care, provided transport money to go to the clinic/dispensary, reminded to give the infant prophylaxis, helped giving the infant prophylaxis medication, collected medication for the woman or infant, encouraged specific infant feeding, and encouraged pediatric HIV testing.
These are assessed in the follow-up questionnaires completed at 12 months post-partum.
|
12 months post-partum
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Lisa Abuogi, MD, MSc, University of Colorado, Denver
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Palmer MJ, Henschke N, Bergman H, Villanueva G, Maayan N, Tamrat T, Mehl GL, Glenton C, Lewin S, Fonhus MS, Free C. Targeted client communication via mobile devices for improving maternal, neonatal, and child health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013679. doi: 10.1002/14651858.CD013679.
- Abuogi LL, Onono M, Odeny TA, Owuor K, Helova A, Hampanda K, Odwar T, Onyango D, McClure LA, Bukusi EA, Turan JM. Effects of behavioural interventions on postpartum retention and adherence among women with HIV on lifelong ART: the results of a cluster randomized trial in Kenya (the MOTIVATE trial). J Int AIDS Soc. 2022 Jan;25(1):e25852. doi: 10.1002/jia2.25852.
- Helova A, Onono M, Abuogi LL, Hampanda K, Owuor K, Odwar T, Krishna S, Odhiambo G, Odeny T, Turan JM. Experiences, perceptions and potential impact of community-based mentor mothers supporting pregnant and postpartum women with HIV in Kenya: a mixed-methods study. J Int AIDS Soc. 2021 Nov;24(11):e25843. doi: 10.1002/jia2.25843.
- Onono M, Odwar T, Wahome S, Helova A, Bukusi EA, Hampanda K, Turan J, Abuogi L. Behavioral Interventions can Mitigate Adverse Pregnancy Outcomes Among Women Conceiving on ART and Those Initiated on ART During Pregnancy: Findings From the MOTIVATE Trial in Southwestern Kenya. J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):46-55. doi: 10.1097/QAI.0000000000002521.
- Wanga I, Helova A, Abuogi LL, Bukusi EA, Nalwa W, Akama E, Odeny TA, Turan JM, Onono M. Acceptability of community-based mentor mothers to support HIV-positive pregnant women on antiretroviral treatment in western Kenya: a qualitative study. BMC Pregnancy Childbirth. 2019 Aug 13;19(1):288. doi: 10.1186/s12884-019-2419-z.
- Odeny TA, Onono M, Owuor K, Helova A, Wanga I, Bukusi EA, Turan JM, Abuogi LL. Maximizing adherence and retention for women living with HIV and their infants in Kenya (MOTIVATE! study): study protocol for a randomized controlled trial. Trials. 2018 Jan 29;19(1):77. doi: 10.1186/s13063-018-2464-3.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 maj 2014
Primärt slutförande (Faktisk)
1 april 2019
Avslutad studie (Faktisk)
1 mars 2021
Studieregistreringsdatum
Först inskickad
11 mars 2015
Först inskickad som uppfyllde QC-kriterierna
2 juli 2015
Första postat (Uppskatta)
7 juli 2015
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
26 april 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 april 2021
Senast verifierad
1 april 2021
Mer information
Termer relaterade till denna studie
Nyckelord
- Retention i vården
- Spädbarns hälsa
- Koppling till vård
- Vertikal transmission
- Tidig diagnos av spädbarn
- HIV-överföring
- Vidhäftning av antiretroviral terapi
- Förebyggande av överföring från mor till barn
- Gemenskapens mentor mammor
- Mobile phone text messaging
- Maternal CD4/viral belastning
- Acceptans av interventioner
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- Långsamma virussjukdomar
- HIV-infektioner
- Förvärvat immunbristsyndrom
Andra studie-ID-nummer
- 14-0331
- R01HD080477-01 (U.S.S. NIH-anslag/kontrakt)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .